Ryzneuta Disease Interactions
There is 1 disease interaction with Ryzneuta (efbemalenograstim alfa).
Moderate
Efbemalenograstim alfa-vuxw (applies to Ryzneuta) sickle cell disorders
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Sickle Cell Anemia
Efbemalenograstim alfa-vuxw may cause severe and potentially fatal sickle cell crisis in patients with sickle cell disorders. If sickle cell crisis occurs, discontinue Efbemalenograstim alfa-vuxw.
References (1)
- (2023) "Product Information. Ryzneuta Prefilled Syringe (efbemalenograstim alfa)." Evive Biotech
Switch to consumer interaction data
Ryzneuta drug interactions
There are 179 drug interactions with Ryzneuta (efbemalenograstim alfa).
Report options
QR code containing a link to this page
More about Ryzneuta (efbemalenograstim alfa)
- Ryzneuta consumer information
- Check interactions
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: colony stimulating factors
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
